Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.
Post–cardiac arrest care is increasingly structured around survivorship, with standardized patient-reported assessments supporting multidisciplinary follow-up.
The US Food and Drug Administration approves pitolisant (WAKIX) tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
The 2025 US Department of Veterans Affairs and US Department of Defense asthma guideline introduces 21 evidence-based recommendations for primary care, redefining stepwise treatment, comorbidity management, and reliever strategy.